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more efficient recruitment of the neural system involved. It 
can be concluded that GH treatment for 6 months improved 
the long-term as well as the working memory in patients 
with GHD, and this was associated with decreased brain ac-
tivation in the ventrolateral prefrontal cortex. GH substitu-
tion in GHD patients is beneficial for cognitive functioning, 
the effects of which can be visualized by means of neuroim-
aging. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 The function of the growth hormone (GH)-insulin-like 
growth factor I (IGF-I) axis as well as the cognitive func-
tioning decline with aging. In healthy elderly, mood and 
cognition are positively related to the level of IGF-I. More 
specifically, the IGF-I levels appear to be related to cogni-
tive performance, short-term memory, and cognitive flex-
ibility  [1, 2] . Other studies have shown an association be-
tween GH deficiency (GHD) and cognition, especially 
memory performance. Patients with both adult-onset 
(AO) and childhood-onset (CO) GHD were found to have 
a depressed mood and an impaired cognitive functioning 
 [2, 3] . GH substitution improved the cognitive function, 
as observed in attention and memory tasks  [4] , in a face 
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 Abstract 
 Patients with childhood-onset growth hormone (GH) defi-
ciency (GHD) show impairments in mood and cognitive 
functioning which may resolve following GH substitution. 
Brain functional magnetic resonance imaging (fMRI) during 
performance of a memory task was used to assess the cere-
bral activity of such patients. Thirteen childhood-onset GHD 
patients (mean age 27.3  8 6.9 years) were included in a dou-
ble-blind, placebo-controlled study. The effects of 6 months 
of GH replacement or placebo therapy were studied using 
neuropsychological tests and fMRI. One patient was exclud-
ed from the study due to noncompliance with the protocol. 
Six months of GH substitution in these GHD patients resulted 
in improved memory functioning, both for long-term and 
working memory. fMRI showed activations during the work-
ing memory task in prefrontal, parietal, motor, and occipital 
cortices, as well as in the right thalamus and anterior cingu-
late cortex. Decreased activation in the ventrolateral pre-
frontal cortex was observed after GH treatment as compared 
with placebo treatment, indicating decreased effort and 
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recognition test  [5] , and in the symbol-number associa-
tion subtest of the Wechsler Adult Intelligence Scale  [6] . 
However, other studies in GHD patients reported no effect 
of GH substitution on the cognitive performance  [7, 8] . 
The available data in a recent meta-analysis on GH and 
cognitive functioning in patients with GHD was too lim-
ited to draw conclusions with respect to the impact of GH 
treatment on cognition  [9] . In a study on the effects of GH/
IGF-I on the EEG activity, the importance of the GH-IGF-
I axis in functioning of the anterior cingulate cortex was 
shown in patients with CO-GHD  [10] . Impaired cognitive 
functioning and abnormal N-acetylaspartate/choline ra-
tios in the brain, indicating a reduced neuronal integrity 
 [11] , were observed in patients with CO-GHD. Oertel et 
al.  [12] performed a randomized double-blind, placebo-
controlled trial over 6 months in 18 adults with GHD. Im-
provement of the attentional performance was observed 
after 3 and 6 months of GH substitution therapy, but there 
was no effect on verbal memory or verbal intelligence. 
 The mechanisms underlying the relation between GH 
and cognitive functioning are not yet fully understood. 
There are indications that GH can cross the blood-brain 
barrier  [13] , while choroid plexus, hypothalamus, puta-
men, and thalamus have been shown to possess binding 
sites for GH and IGF-I  [14, 15] . Moreover, GH treatment 
has been found to reduce the concentration of homovanil-
lic acid, a dopamine metabolite, in cerebrospinal fluid  [13, 
16, 17] . As the hippocampus is known to contain high 
levels of dopamine, particularly this structure may be af-
fected by GH treatment which might explain the connec-
tion between GH treatment and cognitive functions, in 
particular memory. 
 The present study was designed to investigate the effect 
of GH substitution therapy in patients with CO-GHD on 
cognitive functioning, especially memory performance. 
To elucidate this issue, we used functional magnetic reso-
nance imaging (fMRI). This technique provides a means 
to investigate the brain function in a noninvasive manner 
during performance of a memory task. fMRI provides in-
formation on the oxygenation state of the brain using the 
blood oxygenation level dependent response. 
 We performed a previous imaging study  [18] using 
positron emission tomography to measure the brain acti-
vation in healthy elderly subjects with either high or low 
serum IGF-I levels. This positron emission tomography 
activation study revealed a difference in cerebral blood 
flow in subjects with higher IGF-I levels as compared with 
subjects with lower IGF-I levels  [18] . We have recently 
shown  [19] that both cognition and brain activity mea-
sured with fMRI during a working memory task were dif-
ferent in 13 patients with CO-GHD as compared with 
healthy matched controls. The GHD patients had a sub-
normal memory speed, but a normal quality of memory 
performance. The patients allocated more brain activity 
to areas involved in working memory, e.g., dorsolateral/
ventrolateral prefrontal cortex, anterior cingulate cortex, 
and parietal cortex, than control subjects. 
 In the present study, we hypothesized that GH substi-
tution in GHD patients would normalize working mem-
ory speed and/or performance and induce changes in as-
sociated brain activity. We expected that GH substitution 
would improve the working memory performance and al-
ter the activity in brain areas associated with working 
memory (prefrontal and parietal cortices). 
 Patients and Methods 
 Patients 
 In the present study, 13 patients with CO-GHD were included, 
with a mean age of 27.3  8 6.9 years. Inclusion criteria were diag-
nosis of CO-GHD confirmed with an insulin tolerance test or an-
other GH stimulation test and optimal substitution for the other 
pituitary hormones. Exclusion criteria were neuropsychiatric dis-
eases and noncompliance. All patients who were on GH therapy
(n = 8) had to stop GH treatment for a 3-month washout period 
before entering the study. 
 Education levels were assessed, using a 5-point scale, defined in 
conformity with the levels of education specified by the European 
Community  [20] . These levels ranged from (1) school education 
not completed, subject attended school for the mentally or physi-
cally handicapped, to (5) completed university/academy educa-
tion. The mean educational level of the patient group, i.e., 3.8  8 
0.7, corresponds to at least 10 years of education and training, in-
dicating an average-educated population. 
 All subjects gave written informed consent. The study was ap-
proved by the Medical Ethical Committee of the VU University 
Medical Center and was conducted according to the principles of 
the Helsinki Declaration. 
 Procedures 
 After a 3-month washout period following discontinuation of 
GH substitution, the IGF-I level was tested twice to confirm the 
GHD state. At the start of the study, neuropsychological and event-
related fMRI scannings were performed. The baseline data from 
the 13 patients with CO-GHD as compared with healthy controls 
were described previously  [19] . Thereafter, the patients were ran-
domized either to active treatment with GH (Pfizer, Capelle a/d 
Ijssel, the Netherlands) or placebo for a period of 6 months. The 
treatment was given in a double-blind manner, and an endocri-
nologist not involved in the study determined the GH dosages ac-
cording to the measured plasma IGF-I levels during treatment. 
Aim was to achieve IGF-I levels normal for age  8 0.5 SD. GH or 
placebo preparation of identical appearance was daily injected be-
fore nighttime. Both neuropsychological and fMRI scannings were 
repeated after 6 months. 
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 Neuropsychological Tests 
 The following tests were selected from the Neurobehavioral Ed-
ucation System (NES)  [21] and were administered by means of a 
PC. 
 Mood: A shortened Dutch version of the Profile of Mood States 
(POMS) consisting  of 32 items  [22] was used for the assessment of 
depression, anger, fatigue, tension, and vigor. Higher scores for de-
pression (8–40), anger (7–35), fatigue (6–30), and tension (6–30) 
reflect a negative mood; higher scores for vigor (5–25) reflect a bet-
ter mood. 
 Memory: For the assessment of short-term memory, attention, 
and concentration, the participants were asked to repeat a string of 
digits by using the keyboard in the original order (digit span for-
ward) or in the reverse order (digit span backward). Increasingly 
longer spans of digits were presented, until the subjects made two 
errors at the same span length. The lengths of the longest spans 
correctly repeated forwards and backwards were scored. For the 
associated learning task  [23] , nine word pairs consisting of a name 
and an occupation are one at a time displayed on a computer screen 
during 3 s. Immediately after the last combination, one of the 
names is shown together with a list of the nine occupations. The 
patients have to press a number on the keyboard that corresponds 
to the occupation applying to the name presented. Then, after feed-
back is given on the screen concerning the correctness of the re-
sponse, the next name and the nine occupations are presented. In 
total nine trials are successively presented, until each of the nine 
names is paired with the nine occupations. The whole test was re-
peated twice, to allow the subject to learn as many paired names 
and occupations as possible. This recognition test measures short-
term verbal learning (maximum score 27). For the assessment of 
the long-term memory, unexpectedly, after an interval of 60 min, 
the subjects had to match again each one of the nine names pre-
sented in the associated learning delayed recognition task with one 
of the nine occupations (maximum score 9). This time no feedback 
was given. 
 Imaging Paradigm 
 The task performed during neuroimaging was a parametric 
delayed non-match to sample (DNMTS) task, adapted in our lab-
oratory. This is a working memory task specifically measuring 
verbal recognition memory. A detailed explanation of this task 
has been reported previously  [19] . During the DNMTS task, a 
series of letters was presented on a computer screen for 4 s, and 
subjects were instructed to read the series of letters and memorize 
them. After a 3-second delay (blank screen), two cue letters, one 
left and one right on the screen, were shown during 7 s. The sub-
jects were requested to select the letter not present in the previous 
string, using the button press compatible with the location of this 
letter on the screen (left or right). During baseline trials, the letter 
string was shown throughout the 3-second retention period and 
the 7-second cue letter presentation. Also during these trials, the 
subjects were requested to select the letter not present in the pre-
vious string by pressing the left or right button ( fig. 1 ). Before the 
presentation of each series of letters, the subjects were informed 
(on the screen) on whether the upcoming set of letters had to be 
remembered (activation condition) or not (baseline condition). 
Trial information (remember or do not remember) was present-
ed on the screen for 3 s, followed by a 2-second blank screen. In-
tertrial interval was 3 s. Different lengths of letter strings were 
presented in random order (3, 4, 5, 6, 7, or 8 letters), and activa-
tion and baseline trials were also presented in random order. To 
ensure that the participants were familiar with the task, the test 
was explained and practiced outside the scanner before MRI was 
started. To obtain an activation and baseline response, the sub-
jects were instructed to perform as accurately and as fastly as pos-
sible within the given time limits. No feedback regarding correct 
t = 3 st = 0 s t = 5 s t = 9 s t = 12 s t = 19 s t = 22 s
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 Fig. 1.  a Flow chart of the time sequence (s) of presentation of the 
working memory task during fMRI scanning.  b Graph of screens 
presented during an activation trial in the working memory task. 
Trial information (remember or do not remember) was presented 
on the screen for 3 s, thereafter the screen was blank for 2 s. A series 
of letters was presented for 4 s, after which the screen was blank for 
a 3-second delay interval. After this delay, one of the letters togeth-
er with a novel letter appeared on the screen for 7 s. Thereafter the 
screen was blank for 3 s (constant pause), followed by the next series 
of letters.  c Graph of screens presented during a baseline trial in the 
working memory task. In this condition, the series of letters was 
presented for 7 s, i.e., throughout the 4-second familiarization pe-
riod and the 3-second delay interval. 
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answers was provided during the task performance. A total of 48 
series of letters were successively presented in random order (12 
baseline trials, 36 activation trials). Main cognitive outcomes 
were number of correct responses and reaction time (RT) in mil-
liseconds. 
 Neuroimaging 
 For fMRI an echo planar imaging (EPI) sequence (repetition 
time 3.045 s, echo time 45 ms, flip angle 90°) was used, creating 
transversal whole-brain acquisitions (35 slices, 3  ! 3-mm in-plane 
resolution, slice thickness 2.5 mm with a 0.5-mm interslice gap). In 
total 350 EPI volumes per subject were scanned. A T 1 -weighted 
structural MRI scan was acquired using a 1.5-tesla Magnetom So-
nata MR scanner (Siemens, Erlangen, Germany; magnetization-
prepared rapid acquisition gradient echo, inversion time 300 ms, 
repetition time 15 ms, echo time 7 ms, flip angle 8°, voxel size 1  ! 
1  ! 1.5 mm). These structural MRI scans were used for correct 
anatomical interpretation of the results obtained by fMRI scan-
ning. 
 Hormone Assays 
 Blood samples for IGF-I level determinations were drawn at the 
start of the study and after 3 and 6 months of treatment. Blood 
samples were also drawn for determination of the other pituitary 
functions. The serum concentrations of thyroid-stimulating hor-
mone, free T 3 , free T 4 , cortisol, prolactin, luteinizing hormone, fol-
licle-stimulating hormone, estradiol (females), and testosterone 
(males) were measured according to standardized techniques using 
commercially available radioimmunoassays. The plasma IGF-I lev-
els were also measured using a commercially available assay (che-
miluminescence; Nichols Institute Diagnostics, San Juan Capist-
rano, Calif., USA). The detection limit for IGF-I is 0.6 nmol/l. The 
intra-assay coefficient of variation is 3% at a serum IGF-I level of 
20 nmol/l. The interassay coefficient of variation is 6% at a serum 
IGF-I level of 33 nmol/l and 8% at a serum IGF-I level of 7 nmol/l. 
The plasma IGF-binding protein 3 (IGFBP-3) levels were measured 
using a commercially available immunoradiometric assay (Diag-
nostic Systems Laboratories, Webster, Tex., USA) with a detection 
limit of 0.4 mg/l. 
 Image Processing 
 Imaging data were analyzed using Statistical Parametric Map-
ping (SPM2) software, developed by the Wellcome Department of 
Cognitive Neurology (London, UK). We discarded the first two 
EPI volumes of each fMRI time series to allow for magnetic satura-
tion. Time series were corrected for differences in slice time acqui-
sition and realigned to correct for subject movement. Thereafter, 
the images were spatially normalized to anatomical standard space, 
as defined by the SPM EPI template, and resampled to a voxel size 
of 3  ! 3  ! 3 mm. Data were smoothed using an 8-mm full-width 
half-maximum gaussian filter to increase the signal-to-noise ratio. 
Next, individual analyses were performed using the general linear 
model, with delta functions and a canonical hemodynamic re-
sponse function to model responses of varying length to each stim-
ulus. For each subject, weighted contrasts were computed for main 
effects (activation vs. implicit baseline) and for task load. Main ef-
fects are reported at p  ! 0.005, corrected for multiple comparisons 
using the false detection rate method  [24], with a cluster threshold 
of 5 voxels, unless indicated otherwise. Group-by-task interactions 
were masked using the appropriate main effects. Regions deter-
mined by Talairach coordinates for peak effects were verified using 
anatomical localization. 
 Statistics 
 All analyses for demographic data, hormone values, mood scale 
scores, and task performance were carried out by means of the Sta-
tistical Package for the Social Sciences version 11.5. Variables were 
analyzed by means of multivariate analysis of (co)variance with 
group (GH or placebo treatment) as an independent factor and 
outcome measures as dependent variables. Baseline values were 
used as covariates to correct for differences in baseline values be-
tween treatment groups. DNMTS data comprising RT and number 
of correct responses for series with equal set size were averaged. 
This procedure resulted in six dependent variables for RT and for 
number of correct responses, i.e., regarding set 3, 4, 5, 6, 7, and 8. 
Statistical significance was set at the 0.05 level. Statistical tests for 
cognitive functioning were one-tailed, based on the hypothesis that 
GH substitution would enhance memory. Data are presented as 
mean values  8 SD, unless indicated otherwise. 
 Results 
 fMRI scanning was performed in 13 patients; however, 
1 patient was excluded from the study due to noncompli-
ance with the treatment protocol. There were no changes 
in other medications across the 6-month study. Five pa-
tients received GH treatment, and 7 patients received pla-
cebo treatment. The patient characteristics are shown in 
 table 1 . Six months of GH therapy did result in signifi-
cantly increased values of serum IGF-I and IGFBP-3 (p  ! 
0.005), whereas no significant differences were observed 
in the placebo-treated group. 
 Neuropsychological Tests 
 After 6 months, there was a statistically significant dif-
ference in performance in the associate learning recogni-
tion task (measuring the long-term memory) in favor of 
the group that received GH therapy (p = 0.004). The in-
crease in performance ratings in the GH-treated group 
was statistically significant (p  ! 0.05). In addition, there 
was a trend to a decrease in the RT on the DNMTS task 
during fMRI scanning in the group that received GH (p = 
0.055). For all other neuropsychological scores, there were 
no significant differences between both groups. The mood 
scale scores improved in both groups, while no difference 
between the GH and placebo group was observed. 
 Imaging Data 
 Regions showing a significantly increased blood oxy-
genation level dependent signal for task-versus-baseline 
comparisons across groups (n = 12) are shown in  table 2 . 
We found an increased bilateral activity in dorsolateral 
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prefrontal cortex (DLPFC) and ventrolateral prefrontal 
cortex (VLPFC), as well as in anterior cingulate, parietal, 
occipital, and motor cortices and right thalamus ( fig. 2 ). 
No significant group interactions were found for the task-
versus-baseline comparison. Task load contrasts are pre-
sented in  table 3 . An increased activation linearly associ-
ated with task load was found in parietal cortex and oc-
cipital cortex, as well as bilaterally in DLPFC, anterior 
Table 1. Characteristics of the GHD patients at baseline (BL) and after 6 months (6 M)
GH BL
(n = 5)
Placebo BL
(n = 7)
Treatment 6 M
(n = 5)
Placebo 6 M
(n = 7)
p
Mean age, years 26.686.5 25.687.7
Male:female ratio 2:3 5:2
I-GHD:MPHD 2:3 2:5
Education level 3.880.8 3.380.5
IGF-I, nmol/l 9.884.4 7.682.8 30.086.6 6.582.2 <0.005*
IGFBP-3, mg/l 2.980.6 2.680.5 4.380.7 2.780.6 <0.005*
Number of mistakes on DNMTS task (MRI) 1.281.6 1.081.3 080 1.181.4 0.045*
Mean RT on DNMTS task (MRI), s 1.580.3 1.580.4 1.280.1 1.580.3 0.055
Association learning total 22.483.4 19.082.9 23.283.9 17.685.8 n.s.
Association learning recall 8.480.9 6.982.2 9.080 5.382.2 0.004*
Digit span forward 7.281.1 6.081.0 7.881.3 7.181.1 n.s.
Digit span backward 6.480.9 4.981.7 6.681.4 5.781.6 n.s.
POMS depression 12.885.8 9.081.0 9.682.3 8.681.1 n.s.
POMS anger 10.682.6 9.182.4 7.881.0 8.081.5 n.s.
POMS fatigue 14.687.3 10.484.4 12.488.4 9.083.5 n.s.
POMS vigor 13.481.5 16.185.2 13.484.0 17.784.7 n.s.
POMS tension 8.082.3 9.184.2 7.681.9 8.082.4 n.s.
I-GHD = Isolated GHD; MPHD = multiple hormone deficiencies. For explanation of the other abbreviations see text. 
* p < 0.05. The p values concern comparisons at month 6 between GH and placebo groups correcte for baseline differences.
Table 2. Regions showing significantly increased brain activation 
in the total group (n = 12) during fMRI scanning (task versus im-
plicit baseline)
Region (cortex) Coordinates of peak voxel Z-value BA
X Y Z
VLPFC left
VLPFC right
42
–45
3
12
3
9
5.89
4.24
45
45
DLPFC anterior
DLPFC posterior
42
60
33
9
15
21
4.69
4.63
46
46
Anterior cingulate 9 9 36 4.49 24
Parietal cortex left
Parietal cortex right
54
–42
–30
–45
45
45
6.30
3.95
40
40
Thalamus right –6 –9 –3 3.87
Motor cortex 45
–24
–21
–21
–60
57
5.91
3.57
4
4
Occipital 27
–6
–69
–93
–6
0
5.18
3.85
18/19
17
BA = Brodmann area. For explanation of the other abbrevia-
tions see text. Cluster size threshold 5 voxels.
Table 3. Regions showing significantly increased brain activation 
in the total group (n = 12) during fMRI scanning (for task load ef-
fect)
Region (cortex) Coordinates of peak voxel Z-value BA
X Y Z
VLPFC left 36 24 0 5.89 45
DLPFC left
DLPFC right
54
–42
12
30
33
30
4.85
5.3
9
9
Anterior cingulate –6 12 48 5.02 32
Anterior prefrontal –36 54 15 4.43 10
Parietal cortex left
Parietal cortex right
30
–39
–60
–51
39
39
5.74
4.04
40
40
Temporal-parietal 45 –60 –12 4.07 7
Occipital 24
–24
–87
–69
3
48
4.47
3.78
37/19
17
BA = Brodmann area. For explanation of the other abbrevia-
tions see text. Cluster size threshold 5 voxels.
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cingulate cortex, anterior prefrontal cortex, and left VLP-
FC ( fig. 3 ). Task-by-group interactions in favor of the 
group that received placebo were found in the left VLPFC 
( fig. 4 ). The brain activity in this region decreased in pa-
tients who received GH therapy as compared with those 
who received placebo. 
 Discussion 
 With regard to neuropsychological functioning, this 
double-blind, placebo-controlled study performed in 12 
patients with CO-GHD showed that GH therapy improved 
the long-term memory, as measured with the associate 
learning recall task. We also observed an increased speed 
of working memory performance during fMRI scanning, 
as the RTs decreased after GH treatment as compared with 
placebo treatment. These results are in line with those of 
previous studies which showed that the activity of the so-
matotropic axis is associated with neurocognitive func-
tioning. However, the number of intervention studies on 
this topic is limited. Deijen et al.  [4] showed normalization 
in memory performance during 2 years of GH substitution 
in CO-GHD men. The first 6 months of this study were 
placebo controlled which showed that the associate learn-
ing task improved after 6 months of GH therapy as com-
pared with placebo. During a 10-year follow-up period of 
these patients, improvement in memory performance as 
compared with baseline was still found after 10 years of GH 
therapy  [25] . Another intervention study on cognitive 
 Fig. 2. Brain activation across sessions for all patients (n = 12) for 
task versus baseline (thresholded at p  ! 0.001, extent  1 5 voxels). 
Yellow color expresses more brain activation (on a scale of red, or-
ange, and yellow). 
 Fig. 3. Brain activation across sessions for all patients (n = 12) for 
task load (thresholded at p  ! 0.001, extent  1 5 voxels). Yellow color 
expresses more brain activation (on a scale of red, orange, and yel-
low). 
 Fig. 4. Task load by group (placebo vs. GH therapy) interaction in 
the left ventrolateral cortex. 
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functioning  [26] did not report any beneficial effects of 
GH substitution as compared with placebo. In this ran-
domized, double-blind, placebo-controlled study, 40 men 
with AO-GHD received GH or placebo for 18 months. Fol-
lowing 18 months of GH replacement therapy, there were 
no significant changes in the cognitive function. These au-
thors concluded that chronic low-dose GH replacement 
therapy did not result in significant beneficial effects on 
the cognitive function. A recent placebo-controlled study 
done in 18 patients with AO-GHD showed that 6 months 
of GH therapy improved attentional functioning as com-
pared with placebo. However, verbal memory and nonver-
bal intelligence did not improve  [12] . 
 In the present study, the mood scale scores improved 
after therapy in all patients, and the scores were not dif-
ferent between treatment groups. This can be explained 
by a placebo effect on mood which is frequently seen after 
GH treatment when evaluating the quality of life. In a re-
cently conducted meta-analysis  [9] , we found 6 months of 
GH treatment to be as effective as placebo treatment in 
improving the quality of life. 
 The present imaging data showed brain activation in 
the parietal and prefrontal areas during performance of 
the working memory task. Specifically, we found activa-
tions in DLPFC, VLPFC, and anterior cingulate and ante-
rior prefrontal cortices. These areas are well-known work-
ing memory areas and have been found in numerous oth-
er studies on working memory [for a review, see ref.  27] . 
The VLPFC activity may reflect maintenance (storage) 
and subvocal rehearsal. DLPFC recruitment has been ob-
served during manipulation working memory tasks, but 
also during maintenance tasks, in particular at higher 
memory loads. In addition, the anterior cingulate cortex 
is involved in response selection and error monitoring 
 [28], whereas posterior parietal activity has been explained 
as being due to storage as well as attentional processes. We 
observed robust activation during the working memory 
task, as well as for task-versus-baseline comparisons and 
for task load, the latter presumably being more specific 
 [29, 30] . Interaction effects were found in the VLPFC for 
the task load contrast. After GH substitution, we observed 
a decreased activity in the VLPFC as compared with pla-
cebo treatment. These results are in line with those of our 
previous study  [19] , in which we found an increased brain 
activation in GHD patients as compared with healthy 
matched controls. The most likely explanation is that the 
decreased activity in a working-memory-associated re-
gion reflects decreased effort and more efficient recruit-
ment of the neural system associated with the working 
memory. An abnormally increased dorsolateral and/or 
anterior cingulate activity during working memory tasks 
has been observed in various neuropsychiatric disorders 
such as schizophrenia  [31] and obsessive-compulsive dis-
orders  [32] . In these studies, the patient performance was 
usually, but not invariably, impaired relative to control 
subjects. For example, in schizophrenia patients, aberrant 
patterns of brain activity have been found despite near-
normal performance  [33] . In the present study, interac-
tion effects were observed only in the left VLPFC, where-
as other differences failed to reach significance which may 
have been due to our small sample size. Alternatively, the 
treatment duration (6 months) may have been too short. 
 In addition, it could be argued that our design was not 
balanced with regard to the number of activation trials 
(36) and baseline trials (12) presented in our DNMTS 
task. However, in view of the length of each trial (approx-
imately 9 s), the number of observations (scans) for each 
condition appears to be sufficient. Finally, the trend found 
towards improvement in the speed of the working mem-
ory performance might have reached significance with an 
increased number of patients included in this study. 
 From other brain imaging studies, there is some evi-
dence that female sex steroid hormones modulate brain 
metabolism and blood flow both during cognitive activity 
and during the baseline period [for a review, see ref.  34] . 
Estrogen replacement therapy in postmenopausal women 
increased the regional cerebral blood flow in the temporal 
lobe during the resting state. Testosterone replacement 
has been shown to enhance brain perfusion in the mid-
brain in hypogonadal men  [35] . 
 In summary, in line with previous neuropsychological 
findings, data from the present study demonstrate that 
GH substitution in GHD patients improves long-term 
and working memory functions. In addition, the present 
fMRI data indicate increased efficiency of working-mem-
ory-associated cortical regions after GH substitution as 
compared with placebo. However, this interpretation 
should be made with caution in view of our small sample 
size. Future research should aim at replicating these find-
ings in a larger group and at determining whether GH 
substitution also leads to improved memory function in 
other patients groups, such as patients with AO-GHD, or 
in healthy elderly subjects with decreased IGF-I levels. 
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